HC Wainwright Has Negative Forecast for SGMO FY2026 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Stock analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Sangamo Therapeutics in a research note issued on Thursday, April 2nd. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings of ($0.17) per share for the year, down from their previous estimate of ($0.10). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q4 2026 earnings at ($0.04) EPS and FY2027 earnings at $0.00 EPS.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Monday, March 30th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.12). Sangamo Therapeutics had a negative net margin of 310.81% and a negative return on equity of 1,070.18%. The firm had revenue of $14.23 million during the quarter, compared to analyst estimates of $40.25 million.

Several other analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Sangamo Therapeutics to a “strong sell” rating in a research report on Saturday, January 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sangamo Therapeutics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $5.50.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ SGMO traded down $0.02 during trading on Tuesday, hitting $0.26. 4,832,267 shares of the company traded hands, compared to its average volume of 6,545,080. The business’s fifty day moving average is $0.38 and its 200 day moving average is $0.47. Sangamo Therapeutics has a fifty-two week low of $0.21 and a fifty-two week high of $0.84. The firm has a market capitalization of $108.95 million, a price-to-earnings ratio of -0.58 and a beta of 1.49.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its holdings in Sangamo Therapeutics by 2.1% during the second quarter. Geode Capital Management LLC now owns 2,332,279 shares of the biopharmaceutical company’s stock valued at $1,263,000 after purchasing an additional 48,829 shares during the period. XTX Topco Ltd bought a new position in shares of Sangamo Therapeutics during the 2nd quarter worth $41,000. Invesco Ltd. increased its holdings in Sangamo Therapeutics by 40.6% in the 2nd quarter. Invesco Ltd. now owns 680,452 shares of the biopharmaceutical company’s stock worth $368,000 after acquiring an additional 196,558 shares during the last quarter. Engineers Gate Manager LP increased its holdings in Sangamo Therapeutics by 101.7% in the 2nd quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 44,078 shares during the last quarter. Finally, Wasatch Advisors LP raised its stake in Sangamo Therapeutics by 17.7% in the 2nd quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company’s stock valued at $4,376,000 after acquiring an additional 1,215,653 shares during the period. 56.92% of the stock is currently owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.